5.185

2.90% -0.155

Mannkind Corp (MNKD)

Overview News Price History Option Chain Financials Why MNKD Down? Discussions Forecast Stock Split

Mannkind Corp stock is traded at $5.185, with a volume of 1.31M. It is down -2.90% in the last 24 hours and down -6.91% over the past month. MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Previous Close:

$5.34

Open:

$5.35

24h Volume:

1.31M

Relative Volume:

0.55

Market Cap:

$1.58B

Revenue:

$248.37M

Net Income/Loss:

$11.74M

P/E Ratio:

103.70

EPS:

0.05

Net Cash Flow:

$18.24M

1W Performance:

-9.04%

1M Performance:

-6.91%

6M Performance:

-14.72%

1Y Performance:

+15.22%

1-Day Range:

$5.165

$5.39

1-Week Range:

$5.15

$5.77

52-Week Range:

$3.97

$7.63

Mannkind Corp Stock (MNKD) Company Profile

Name

Mannkind Corp

Sector

Healthcare (1188)

Industry

Biotechnology (679)

Phone

818-661-5000

Address

1 CASPER STREET, DANBURY, CA

Employee

407

Twitter

@MannKindCorp

Next Earnings Date

2024-11-07

Latest SEC Filings

MNKD's Discussions on Twitter

Compare MNKD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MNKD Mannkind Corp	5.185	1.58B	248.37M	11.74M	18.24M	0.05
VRTX Vertex Pharmaceuticals Inc	489.00	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	688.49	75.07B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	634.75	37.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.55	31.79B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	112.61	27.34B	3.30B	-501.07M	1.03B	-2.1146

Mannkind Corp Stock (MNKD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-10-25	Initiated	Wedbush	Outperform
Dec-20-24	Initiated	Wells Fargo	Overweight
Dec-19-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Sep-09-24	Resumed	Leerink Partners	Outperform
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Oct-10-23	Initiated	Wedbush	Outperform
May-14-21	Initiated	RBC Capital Mkts	Sector Perform
Dec-24-19	Initiated	Oppenheimer	Outperform
Oct-25-19	Initiated	Cantor Fitzgerald	Overweight
May-14-19	Initiated	BTIG Research	Buy
Mar-04-19	Initiated	SVB Leerink	Outperform
Feb-22-19	Initiated	SVB Leerink	Outperform
Feb-28-18	Downgrade	Maxim Group	Hold → Sell
Nov-01-17	Downgrade	Maxim Group	Buy → Hold
Oct-10-17	Initiated	H.C. Wainwright	Buy
Oct-06-17	Reiterated	Maxim Group	Buy
Aug-11-17	Initiated	Maxim Group	Buy
May-10-16	Reiterated	Piper Jaffray	Underweight
May-10-16	Reiterated	RBC Capital Mkts	Underperform
Jan-06-16	Reiterated	Piper Jaffray	Underweight
Jan-06-16	Reiterated	RBC Capital Mkts	Underperform
Nov-04-15	Downgrade	RBC Capital Mkts	Outperform → Underperform
Sep-09-15	Downgrade	Piper Jaffray	Neutral → Underweight
Aug-03-15	Reiterated	RBC Capital Mkts	Outperform
May-11-15	Downgrade	JP Morgan	Neutral → Underweight
May-11-15	Reiterated	MLV & Co	Hold
Apr-16-15	Reiterated	RBC Capital Mkts	Outperform

View All

Mannkind Corp Stock (MNKD) Latest News

Feb 28, 2025

Decoding MannKind Corp (MNKD): A Strategic SWOT Insight - GuruFocus.com

Feb 28, 2025

Feb 27, 2025

MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question - Seeking Alpha

Feb 27, 2025

MannKind Corporation (NASDAQ:MNKD) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 27, 2025

MannKind: Q4 Earnings Snapshot - mySA

Feb 27, 2025